PTPN1 and metabolic dysfunction-associated steatotic liver disease: In preclinical trials against NAFLD models, ondansetron has been identified as a strong inhibitor of PTP1B activity, demonstrating pronounced pharmacological activity that supports its effectiveness to be used in the therapeutic context.